RAIN THERAPEUTICS

rain-therapeutics-logo

Rain Therapeutics develops targeted therapies for patients with cancer. We begin by identifing cancers with a single, and clear, oncogenic driver and evaluating sub-populations of cancer populations with an unmet need, where standards of care are ineffective. Our global scientific and thought-leader network drives our asset and technology identification to match these cancers with small molecule therapeutics targeted at treating specific cancer mutations.

#SimilarOrganizations #People #Financial #Website #More

RAIN THERAPEUTICS

Social Links:

Industry:
Biotechnology Health Care Therapeutics

Founded:
2017-01-01

Address:
Fremont, California, United States

Country:
United States

Website Url:
http://www.rainthera.com

Total Employee:
1+

Status:
Active

Contact:
+1 510-953-5559

Email Addresses:
[email protected]

Total Funding:
82.36 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Amazon IPv6 Google Apps For Business Google Maps


Similar Organizations

cradle-genomics-logo

Cradle Genomics

Cradle Genomics is a creator of a novel prenatal testing methodology

topokine-therapeutics-logo

Topokine Therapeutics

Topokine is a Boston-based, clinical-stage biotechnology company.


Current Advisors List

robert-doebele_image

Robert Doebele Chair of the scintific advisory board @ Rain Therapeutics
Advisor

Current Employees Featured

richard-bryce_image

Richard Bryce
Richard Bryce Chief Medical Officer @ Rain Therapeutics
Chief Medical Officer
2021-04-01

dharmendra-singh_image

Dharmendra Singh
Dharmendra Singh Senior Scientist @ Rain Therapeutics
Senior Scientist
2020-10-01

avanish-vellanki_image

Avanish Vellanki
Avanish Vellanki Chairman & Ceo @ Rain Therapeutics
Chairman & Ceo
2009-01-01

Founder


avanish-vellanki_image

Avanish Vellanki

robert-doebele_image

Robert Doebele

Stock Details


Company's stock symbol is NASDAQ:RAIN

Investors List

samsara-biocapital_image

Samsara BioCapital

Samsara BioCapital investment in Series B - Rain Therapeutics

logos-capital_image

Logos Capital

Logos Capital investment in Series B - Rain Therapeutics

cormorant-asset-management_image

Cormorant Asset Management

Cormorant Asset Management investment in Series B - Rain Therapeutics

perceptive-advisors_image

Perceptive Advisors

Perceptive Advisors investment in Series B - Rain Therapeutics

boxer-capital_image

Boxer Capital

Boxer Capital investment in Series B - Rain Therapeutics

janus-henderson-investors_image

Janus Henderson Investors

Janus Henderson Investors investment in Series B - Rain Therapeutics

bvf-partners_image

BVF Partners

BVF Partners investment in Series B - Rain Therapeutics

university-of-auckland-inventors-fund_image

University of Auckland Inventors Fund

University of Auckland Inventors Fund investment in Series A - Rain Therapeutics

perceptive-advisors_image

Perceptive Advisors

Perceptive Advisors investment in Series A - Rain Therapeutics

biotechnology-value-fund_image

Biotechnology Value Fund

Biotechnology Value Fund investment in Series A - Rain Therapeutics

Official Site Inspections

http://www.rainthera.com Semrush global rank: 3.59 M Semrush visits lastest month: 4.01 K

  • Host name: aacb0a264e514dd48.awsglobalaccelerator.com
  • IP address: 75.2.70.75
  • Location: Seattle United States
  • Latitude: 47.54
  • Longitude: -122.3032
  • Metro Code: 819
  • Timezone: America/Los_Angeles
  • Postal: 98108

Loading ...

More informations about "Rain Therapeutics"

Rain Oncology

Rain Oncology develops innovative, targeted therapies to help patients with cancer get their life back. We focus on cancers where we can genetically identify patients most likely to benefit โ€ฆSee details»

About Us - Rain Oncology

Rain Oncology was founded in 2017 as a precision oncology company leveraging a deep scientific knowledge of drug mechanism and designing clinical trials with the most appropriate โ€ฆSee details»

Clinical Trials - Rain Oncology

National Organization for Rare Disorders Basket Study The MANTRA-2 trial is designed to evaluate the safety and efficacy of milademetan in patients with advanced or metastatic solid โ€ฆSee details»

Rain Oncology - Crunchbase Company Profile & Funding

Rain Oncology Inc. is a precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit. An oral small molecule โ€ฆSee details»

RAIN THERAPEUTICS INC. - Orphanet

RAIN THERAPEUTICS INC. The documents contained in this website are presented for information purposes only. The material is in no way intended to replace professional medical โ€ฆSee details»

Rain Oncology - LinkedIn

Rain Oncology is a clinical-stage company researching, developing and translating innovative targeted therapies for patients with cancer to help provide them hope to get their lives back. โ€ฆSee details»

Rain Therapeutics Company Profile - Office Locations ... - Craft

Jan 26, 2024ย ยท Rain Therapeutics is a biotechnology company focused on developing small molecule targeted therapeutics for cancer patients. Its approach includes using a tumor โ€ฆSee details»

Rain Oncology Company Profile 2024: Stock Performance

Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. โ€ฆSee details»

Rain Therapeutics Closes $63 Million Series B Financing

Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on targeted therapies for patients with cancer, has closed a $63 million Series B financing.See details»

Avanish Vellanki - CEO and Cofounder at Rain Therapeutics - The โ€ฆ

About. Avanish Vellanki is the CEO and Cofounder at Rain Therapeutics.Prior to this, they served as the Senior Vice President, Chief Business Officer at Aptose Biosciences, Inc. from โ€ฆSee details»

Rain Therapeutics - Work in biotech

Rain Therapeutics is developing targeted therapies for cancer patients. Precision oncology prioritizes pairing drugs with cancer patients and underlies Rainโ€™s development philosophy.See details»

Organization: Rain Therapeutics - Cbonds.com

Rain Therapeutics. Information about the issuer. News and credit ratings. . Tables with accounting and financial reporting.See details»

Sri Ranga Yarlagadda - Director, Corporate Development at

Ranga Yarlagadda has a diverse work experience spanning multiple industries and roles. Ranga is currently serving as the Director of Corporate Development at Rain Oncology since July 2022.See details»

Rain Therapeutics Announces First Patient Dosed in Phase 2

Mar 19, 2019ย ยท Rain Therapeutics Inc. is a privately-held biotechnology company developing biomarker-driven small molecule therapeutics for patients with cancer. Rainโ€™s lead program, โ€ฆSee details»

Rain Therapeutics Appoints Robert Doebele, M.D., Ph.D. as President

NEWARK, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (โ€œRainโ€), a clinical-stage company developing precision oncology therapeutics, today announced the โ€ฆSee details»

Rain Therapeutics Announces License Agreement for the โ€ฆ

Rain Therapeutics Inc. recently announced the signing of an exclusive, worldwide license agreement of a Drexel University research program to Rain for small molecule inhibitors of โ€ฆSee details»

Rain Oncology Inc - Cruelty Free Investing

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is โ€ฆSee details»

Pipeline - Rain Oncology

Establishing the clinical profile of milademetan for patients with TP53 wildtype tumors. Rain is building a pipeline thatโ€™s focused on genetically selecting the patients most likely to benefit โ€ฆSee details»

Ranga Yarlagadda - Rain Oncology - LinkedIn

REF is a global organization that brings together business leaders in peer advisory groups to enhance their leadership skills and business strategies.See details»

Rain Therapeutics Reports Fourth Quarter and Full Year 2021 โ€ฆ

NEWARK, Calif., March3, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today โ€ฆSee details»

linkstock.net © 2022. All rights reserved